Business Wire

Ncardia Signs License Agreement with First Pharmaceutical Partner for Disease Modeling Patent Portfolio

Del

Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate companies gain access to key disease modeling patents from Ncardia.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171012006114/en/

Ncardia is a leader in standardized, validated iPSC assays for safety, phenotypic screening and dise ...

Ncardia is a leader in standardized, validated iPSC assays for safety, phenotypic screening and disease modeling. For scientists conducting cardiovascular and neural safety and efficacy projects, Ncardia is providing tools to facilitate accelerated development of drugs, while replacing animal studies and putting a "human" aspect back into drug discovery. (Graphic: Business Wire)

Ncardia was recently formed through the merger of Axiogenesis and Pluriomics. The two companies have pioneered the development of stem cell derived cells for drug discovery and safety and in particular have advanced disease and tissue modeling applications.

The Ncardia patent portfolio consists of several granted patents in Europe, the USA and Japan. The drug screening and disease modeling technology not only involves patient iPSC cells, induction of the disease phenotype can also be achieved through genetic manipulation, mRNA or siRNA transfection or through chemical or physical induction.

Dr Stefan Braam, CEO Ncardia, commented: “Ncardia mission is to support and enable our clients to make better medicines faster. The combination of iPSC derived disease models with phenotypic screening is an extremely powerful method to identify new drug candidates. This license marks a further step in Ncardia technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and development market."

Roche has now obtained a non-exclusive, worldwide license to the key Ncardia disease modeling patents claiming the use of stem cell derived cells disease models for the discovery & development of novel drug candidates. The financial terms of the agreements are not disclosed.

“This license is the first step of our strategy to make our technology available to the pharmaceutical drug discovery & development market.” Felix von Haniel VP Sales and BD of Ncardia. In addition to disease modeling applications Ncardia is committed to providing the most predictive healthy human cellular models to improve and accelerate safety testing.

Ncardia: Ncardia (www.ncardia.com) believes that stem cell technology will help to get better medicines to patients faster. The company develops, produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The cardiac product portfolio encompasses a broad panel of hiPSC derived Cardiomyocytes (Pluricyte®, Cor.4U® and vCor.4U) as well cardiac fibroblasts (FibroCor.4U). In addition, the company delivers the Cardioplate product line of quality controlled ready to use assay plates. The neural cell portfolio contains the pan-neuronal product CNS.4U®, the peripheral neurons product Peri.4U®, and astrocyte product Astro.4U®.

Ncardia is committed to deliver its clients working assays solutions through in house assay development and extensive support. The company has a wide range of supported applications and compound assay services such as of electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology and toxicology testing. In addition, Ncardia develops and provides its customers with a broad portfolio of cardiovascular services from disease modeling to cardiovascular drug efficacy screening.

Ncardia is based in Belgium, the Netherlands, Germany and in the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis.

Contact information

Media:
Ncardia
Felix von Haniel
felix.haniel@ncardia.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Global Game Exhibition 'G-STAR 2017' Ends with a Big Finale14.12.2017 00:00Pressemelding

The global game exhibition ‘G-STAR 2017’ had attendees in 2,857 booths from 676 companies in 35 countries and was the largest ever held in history; amidst an enthusiastic response from industries and attendees it ended with a big finale. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213005402/en/ G-STAR 2017 Public Area (Photo: Business Wire) ‘G-STAR 2017’ was hosted by the Korea Gaming Industry Association (K-GAMES) and managed by the G-STAR Organizing Committee and the Busan IT Industry Promotion Agency. It was held for four days from November 16 (Thursday) through November 19 (Sunday) at the Busan BEXCO. This was the 13th year for ‘G-STAR’, and it opened its doors to attendees with a variety of contents in an area approximately 55,300 square meters in size which included Exhib

IFF Declares Dividend for Fourth Quarter 201713.12.2017 21:15Pressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, announced that its Board of Directors has declared a regular quarterly cash dividend of $0.69 per share of the Company’s common stock, payable on January 8, 2018 to shareholders of record as of December 29, 2017. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers taste, smell, or feel in fine fragrances and beauty, detergents and household goods, as well as beloved foods and beverages. Our 7,400 team members globally take a

Limelight Networks Enhances DDoS Security Services with Faster Mitigation of Malicious Website Attacks13.12.2017 19:18Pressemelding

Limelight Networks, Inc. (Nasdaq: LLNW), a global leader in digital content delivery, today introduced new capabilities to its DDoS Attack Interceptor Service that provide high-capacity on-network scrubbing and a scalable range of protection measures for web infrastructure, with the ability to easily increase protection as security requirements change. Protecting websites from online attacks and cyber threats is one of the most pressing security challenges today. For example, data from Limelight’s State of Cybersecurity Report: SE Asia shows consumers are very concerned about the security of ecommerce sites, with 72 percent saying they have a negative opinion of a brand after hearing that it has suffered a cyberattack. In addition, 51 percent of online websites feel they are vulnerable to attacks that could have significant financial and b

Interactive Brokers Now Allowing Short Positions in Bitcoin Futures13.12.2017 17:15Pressemelding

Interactive Brokers Group, Inc. (NASDAQ GS: IBKR), a global electronic brokerage firm, will now accept orders for short sales of Cboe Futures Exchange (CFE) Bitcoin futures that began trading on the IBKR platform on Sunday, December 10, 2017. Interactive Brokers requires margin of $40,000 per contract for short sales in CFE Bitcoin futures. Margin on long positions of CFE Bitcoin futures is currently $9,000. “The introduction of short sales was necessitated by the large premium of the January futures contract over the price at which Bitcoin trades on the physical venues,” said Interactive Brokers founder, Chairman and CEO Thomas Peterffy. Interactive Brokers requires customers who wish to trade Bitcoin futures to execute a special agreement acknowledging the risk inherent in the contract. Current and new clients can learn more about trading Bitcoin futures with IBKR a

Sunny Optics Officially Licenses ImmerVision Panomorph Lens Technology for Global Production13.12.2017 12:47Pressemelding

ImmerVision, developer of exclusive and patented panomorph wide-angle imaging technology, is proud to announce that Sunny Optics (Zhongshan) Co., a subsidiary of Sunny Optical Technology (Group) Co. Ltd., a leading manufacturer of integrated optical components and products, has licensed panomorph lens technology for global production, and will deliver its first small form-factor panomorph high-resolution super-wide-angle lenses for smartphones and mobile devices in Q1 2018. Panomorph lens technology combines state-of-the-art optical design and advanced, optimized algorithms, including low-power dewarping, to produce high-resolution super-wide-angle images without distortion, even in low light conditions. Sunny Optical is the largest Chinese lens supplier for the most popular smartphone brands and OEM applications such as sports cameras, surveillance, 360 image capture, autom

Synacor Launches Enhancements to Zimbra Communications and Collaboration Suite13.12.2017 12:30Pressemelding

Synacor Inc. (NASDAQ:SYNC) today announced the commercial launch of Zimbra 8.8. The easy-to-use collaboration platform comes with new user experience features such as Zimbra Drive for enterprise-level file sync and sharing and Zimbra Chat. The Network Edition features tech stack enhancements including real-time backup, ActiveSync across mobile and desktop, hierarchical storage management (HSM) that enables customers to move archival data to less expensive storage solutions, and improved delegated admin functionality. “Zimbra 8.8 is an exciting update for end users and technical decision makers,” said Marcus Teo, Vice President, Enterprise Sales & Marketing, Synacor. “Customers look to Zimbra for security, privacy and transparency through open code, extensibility, accessibility on multiple devices and deployment flexibility. This update builds on these tenets and incorporates enhancemen

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom